NEW YORK – BC Platforms said on Tuesday that it has partnered with analytics giant SAS Institute to provide life sciences and healthcare organizations with curated genomics and other patient data. The companies expect that the partnership will help them break down data silos and ultimately improve prediction of health outcomes.
Zurich-based BC Platforms and Cary, North Carolina-based SAS said that they already have many of the same clients in pharmaceutical development and healthcare delivery. The firms said they will "discover new ways to derive insights" from genomics and other patient data, such as imaging and blood chemistry.
"Big data is not close to reaching its full potential in health," Nino da Silva, deputy managing director for BC Platforms, said in a statement. "But through our partnership, which provides access to carefully curated patient data, including genomic data, we will deliver tangible results that will make a difference to drug development, healthcare provision, and patient outcomes."
Scott McClain, principal industry consultant at SAS, added that the partnership "ensures users get closer to the high-quality genomics and real-world data networks they need to make bold discoveries that drive progress."
The new collaboration adds to BC Platforms' other recent partnerships, including with Singapore Health Services, the African Institute of Everyone Genome, and Cure Duchenne.